Urovant Sciences Ltd. (UROV)
Stock Price:
$9.12 USD
-0.08 (-0.87%)
Updated Jul 14, 2020 12:47 PM EDT - Market open
Key Info
| Market Cap |
280.89M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-146.75M |
| Shares Out |
30.52M |
| EPS (ttm) |
-4.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 14, 2020 |
| Last Price |
$9.12 |
| Previous Close |
$9.20 |
| Change ($) |
-0.08 |
| Change (%) |
-0.87% |
| Day's Open |
9.13 |
| Day's Range |
9.00 - 9.28 |
| Day's Volume |
39,346 |
| 52-Week Range |
6.55 - 15.98 |
More Stats
| Market Cap |
280.89M |
| Enterprise Value |
319.92M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
30.52M |
| Float |
5.47M |
| EPS (basic) |
-4.82 |
| EPS (diluted) |
-4.82 |
| FCF / Share |
-3.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
918,890 |
| Short Ratio |
6.87 |
| Short % of Float |
11.57% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
14.26 |
| Revenue |
n/a |
| Operating Income |
-138.97M |
| Net Income |
-146.75M |
| Free Cash Flow |
-102.85M |
| Net Cash |
-39.03M |
| Net Cash / Share |
-1.27 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-106.12% |
| ROE |
-1,750.72% |
| ROIC |
-250.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$23.67*
(159.54% upside)
Low
19.0
Current: 9.12
High
28.0
Target: 23.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -139 | -111 | -37.00 | -27.06 |
| Net Income | -147 | -111 | -37.07 | -26.97 |
| Shares Outstanding | 30.42 | 25.15 | 17.12 | 2.67 |
| Earnings Per Share | -4.82 | -4.43 | -2.16 | -10.10 |
| Operating Cash Flow | -102 | -109 | -34.09 | -25.26 |
| Capital Expenditures | -0.77 | -0.59 | -0.52 | - |
| Free Cash Flow | -103 | -110 | -34.61 | -25.26 |
| Cash & Equivalents | 51.66 | 85.60 | 7.19 | 4.77 |
| Total Debt | 90.69 | 13.53 | - | - |
| Net Cash / Debt | -39.03 | 72.06 | 7.19 | 4.77 |
| Assets | 63.30 | 100 | 12.98 | 4.78 |
| Liabilities | 121 | 25.35 | 5.91 | 0.87 |
| Book Value | -58.01 | 74.77 | 7.07 | 3.91 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Urovant Sciences Ltd. |
| Country |
United Kingdom |
| Employees |
70 |
| CEO |
James A. Robinson |
Stock Information
| Ticker Symbol |
UROV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: UROV |
| IPO Date |
September 27, 2018 |
Description
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.